May 14, 2015 8:00 am EDT Heat Biologics Announces Financial Results for the First Quarter Ended March 31, 2015
May 11, 2015 2:04 pm EDT CORRECTING and REPLACING -- Heat Biologics Announces Initiation of Phase 1b Trial of Viagenpumatucel-L (HS-110) in Non-Small Cell Lung Cancer (NSCLC)
May 11, 2015 2:04 pm EDT Heat Biologics Announces Initiation of Phase 1b Trial of Viagenpumatucel-L (HS-110) in Non-Small Cell Lung Cancer (NSCLC)
Apr 22, 2015 8:00 am EDT Heat Biologics, Inc. to Present at the 2015 American Association for Cancer Research Annual Meeting
Apr 15, 2015 8:00 am EDT Heat Biologics, Inc. to Present at the 2015 American Association for Cancer Research Annual Meeting
Mar 27, 2015 8:30 am EDT Heat Biologics Announces Financial Results for the Year Ended December 31, 2014
Mar 16, 2015 2:28 pm EDT Heat Biologics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Over-Allotment Option
Mar 10, 2015 9:42 pm EDT Heat Biologics, Inc. Announces Pricing of Public Offering of $10,660,000 of Common Stock
Mar 09, 2015 8:00 am EDT Heat Biologics, Inc. Receives US FDA Fast Track Designation for HS-410 (Vesigenurtacel L) in Combination With BCG for the Treatment of Non-Muscle Invasive Bladder Cancer